Johnson&Johnson subsidiary responds to "shortage of focus on delivery in many areas": the company is facing supply pressure and challenges due to a significant increase in market demand. Recently, there have been shortages of focus on delivery in many parts of China, and there are even rumors that focus on delivery will be discontinued. In this regard, the reporter called Xi'an Yangsen, a subsidiary of Johnson&Johnson, today, and its staff said that they have not received any notice of delisting from Focus. Focus is an imported packaged drug of the company, and the main raw materials used to produce Focus are under global control. Since 2023, the global demand for Focus Da has been continuously increasing and is expected to exceed the company's production capacity.